PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study - Llombart-Cussac, A; Perez-Garcia, JM; Bellet, M (Cancer Res, 2024)